干细胞样CD8+T细胞在抗肿瘤免疫治疗中的地位与演进效应 |
| |
引用本文: | 林果,姚卓然,王徽,纳飞飞,卢铀.干细胞样CD8+T细胞在抗肿瘤免疫治疗中的地位与演进效应[J].中国肿瘤临床,2023,50(7):373-376. |
| |
作者姓名: | 林果 姚卓然 王徽 纳飞飞 卢铀 |
| |
作者单位: | 四川大学华西医院肿瘤中心胸部肿瘤病房,放疗科,四川大学华西医院临床细胞治疗研究室(成都市610041) |
| |
基金项目: | 本文课题受四川大学华西医院学科卓越发展1·3·5工程项目(编号:ZYJC21003)资助 |
| |
摘 要: | 以抗细胞程序性死亡-1/细胞程序性死亡-配体1(programmed cell death-1/programmed cell death-ligand 1,PD-1/PD-L1)为代表的免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)治疗显现了CD8+T细胞在治疗和可能治愈恶性肿瘤方面的潜力。但仅约20%的患者对ICIs治疗获益,因此阐明CD8+T细胞在免疫微环境中的有效抗肿瘤功能,及其分子和空间的决定因素尤为重要。具有自我更新、增殖分化和杀伤肿瘤细胞能力的干细胞样CD8+T细胞亚群,在介导抗肿瘤免疫效应方面扮演极为重要的角色。本文就干细胞样CD8+T细胞在抗肿瘤免疫循环中的地位与演进效应进行综述。
|
关 键 词: | 干细胞样CD8+T淋巴细胞 免疫治疗 肿瘤微环境 |
收稿时间: | 2022-10-13 |
Role and mechanism of action of stem-like CD8+T cells in anti-tumor immunotherapy |
| |
Institution: | Thoracic Oncology Ward, Department of Radiotherapy, Cancer Center, West China Hospital, Sichuan University, Cancer Center, Laboratory of Clinical Cell Therapy, Chengdu 610041, China |
| |
Abstract: | Anti-programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) as immune checkpoint inhibitors (ICIs) therapy has shown the potential of CD8+T cells in treating and possibly curing malignancies. However, only approximately 20% of patients benefit from ICI therapy. Therefore, it is necessary to elucidate the antitumor function of CD8+T cells in the immune microenvironment and its molecular and spatial mechanism of action. Stem-like CD8+T-cell subsets with the ability of self-renewal, proliferation, differentiation, and killing of tumor cells play a vital role in mediating anti-tumor effects. In this review, we analyzed the roles and evolutionary effects of stem-like CD8+T cells in anti-tumor effects. |
| |
Keywords: | |
|
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
| 点击此处可从《中国肿瘤临床》下载免费的PDF全文 |
|